Nohynek Gerhard J, Duche Daniel, Garrigues Alexia, Meunier Pierre-Alain, Toutain Herve, Leclaire Jacques
L'Oréal Research and Development, Worldwide Safety Department, 25-29 quai Aulagnier, 92600 Asnières, France.
Toxicol Lett. 2005 Sep 15;158(3):196-212. doi: 10.1016/j.toxlet.2005.03.014.
We investigated the biotransformation of the oxidative arylamine (AA) hair dye ingredients [14C]-para-aminophenol (PAP) and [14C]-para-phenylenediamine (PPD) in reconstructed human epidermis and human hepatocytes. Human epidermis quantitatively transformed PAP to its N-acetylated derivative (APAP), whereas hepatocytes transformed PAP to sulfate or glucuronic acid conjugates of APAP or PAP as well as free APAP. Epidermis and hepatocytes converted PPD to N-mono- (MAPPD) and N,N'-di-acetylated (DAPPD) derivatives. At higher concentrations of PPD (250-1000 microM), epidermis or hepatocytes produced more of the MAPPD, whereas concentrations below 250 microM and lower favoured formation of the DAPPD metabolite. When compared with epidermis, human hepatocytes had a three-fold or eight-fold greater capacity for generation of MAPPD or DAPPD, respectively. No evidence of transformation of PAP or PPD to N-hydroxylated derivatives was found in epidermis or hepatocytes. Our results suggest that (i) after dermal absorption of PAP or PPD, humans are systemically exposed to acetylated derivatives; (ii) current in vitro skin absorption studies may be inadapated for determination of human systemic exposure to AAs due to reduced or absent metabolic capacity of non-viable skin; (iii) due to qualitative differences between dermal and hepatic metabolism, oral toxicity studies may be unsuited for the hazard assessment of dermal exposure to AAs; and (iv) use of induced rodent liver S9 metabolic activation systems for in vitro genotoxicity studies may produce misleading results on the hazard of human dermal exposure to AAs. In conclusion, our data support the growing evidence that AAs are transformed in human skin and suggest that current practices of safety assessment of AAs should take these findings into account.
我们在重建的人表皮和人肝细胞中研究了氧化芳胺(AA)染发剂成分[14C]-对氨基苯酚(PAP)和[14C]-对苯二胺(PPD)的生物转化。人表皮将PAP定量转化为其N-乙酰化衍生物(APAP),而肝细胞则将PAP转化为APAP或PAP的硫酸酯或葡萄糖醛酸共轭物以及游离的APAP。表皮和肝细胞将PPD转化为N-单乙酰化(MAPPD)和N,N'-二乙酰化(DAPPD)衍生物。在较高浓度的PPD(250-1000 microM)下,表皮或肝细胞产生更多的MAPPD,而浓度低于250 microM及更低时则有利于DAPPD代谢物的形成。与表皮相比,人肝细胞生成MAPPD或DAPPD的能力分别高出三倍或八倍。在表皮或肝细胞中未发现PAP或PPD转化为N-羟基化衍生物的证据。我们的结果表明:(i)在皮肤吸收PAP或PPD后,人体会全身暴露于乙酰化衍生物;(ii)由于无活力皮肤的代谢能力降低或缺乏,目前的体外皮肤吸收研究可能不适用于确定人体对AA的全身暴露;(iii)由于皮肤和肝脏代谢存在质的差异,口服毒性研究可能不适用于评估皮肤接触AA的危害;(iv)在体外遗传毒性研究中使用诱导的啮齿动物肝脏S9代谢活化系统可能会对人体皮肤接触AA的危害产生误导性结果。总之,我们的数据支持越来越多的证据表明AA在人体皮肤中会发生转化,并表明目前AA的安全评估做法应考虑到这些发现。